← All trials
NCT01844986
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2013
- Primary completion
- Sep 13, 2017
- Completion date
- Mar 29, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 397
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- Gynecologic Oncology GroupCollaborator
- Myrexis Inc.Collaborator
- University of OklahomaOverall official - principal investigator
- Brown UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.